Mazdutide vs Tirzepatide
A glucagon dual agonist vs the approved GIP dual
Mazdutide (Innovent/Eli Lilly) is a GLP-1/glucagon dual agonist furthest along in China; tirzepatide (Mounjaro/Zepbound) is the GLP-1/GIP dual approved across the US and Europe. Here is how the glucagon route compares with the proven incretin standard.
Glucagon vs GIP — two ways to build on GLP-1
Both drugs add a second receptor to GLP-1. Mazdutide adds glucagon receptor agonism, which raises energy expenditure and drives liver-fat reduction; tirzepatide adds GIP, which enhances appetite suppression and the metabolic response and underpins its large, well-proven weight loss.
Mazdutide is most advanced in China, where Phase 3 trials have reported meaningful weight loss and it has moved toward approval; tirzepatide reported roughly 22.5% weight loss in SURMOUNT-1 and is approved for obesity and type 2 diabetes globally.
The big practical difference is geography and stage: tirzepatide is broadly available, while mazdutide’s furthest progress is in China. Cross-trial percentages are not directly comparable.
Mazdutide vs Tirzepatide at a glance
- ⚡Mechanism: GLP-1 + glucagon dual agonist
- ⚡Phase 3 weight loss reported in China’s GLORY program
- ⚡Glucagon adds energy expenditure and liver-fat reduction
- ⚡Furthest along in China; investigational elsewhere
- ⚡Also studied for metabolic liver disease
- ✓Mechanism: GLP-1 + GIP dual agonist
- ✓SURMOUNT-1: about 22.5% mean weight loss at 72 weeks
- ✓Once-weekly subcutaneous pen, no mixing
- ✓FDA/EMA approved for obesity and type 2 diabetes
- ✓Years of real-world safety and efficacy data
Which is relevant for you?
If you are outside China and want an approved, proven option now, tirzepatide is the practical choice — broadly available with extensive Phase 3 data. Mazdutide becomes relevant if you are in a market where it is approved, or if you are specifically interested in the glucagon mechanism for energy expenditure and liver fat.
As mazdutide’s data and approvals expand internationally, this comparison will sharpen; for now, treat the numbers as directional rather than a precise ranking.
Track now, compare later
There is no head-to-head trial of mazdutide and tirzepatide, so the figures come from separate studies. Logging your own response in Shotlee — weight, appetite, side effects, and labs — gives you an objective baseline that makes any future switch evidence-based.
Use this comparison as a framework and confirm the specifics with your healthcare provider.
Mazdutide vs Tirzepatide: Frequently Asked Questions
There is no head-to-head trial. Tirzepatide has approved, well-proven data (about 22.5% weight loss) and is broadly available, while mazdutide’s distinctive feature is its glucagon mechanism and its furthest progress is in China. Cross-trial numbers are only directional.
Mazdutide is a GLP-1/glucagon dual agonist (glucagon adds energy expenditure and liver-fat reduction); tirzepatide is a GLP-1/GIP dual agonist (GIP enhances appetite control). Tirzepatide is approved globally; mazdutide is most advanced in China.
Mazdutide is furthest along in China, where it has advanced through Phase 3 toward approval. In most of the world it remains investigational. Tirzepatide is already approved for obesity and type 2 diabetes.
Mazdutide is developed by Innovent Biologics in partnership with Eli Lilly, primarily for the Chinese market.
Yes. Shotlee logs doses, weight, side effects, and labs for your current protocol, free — ready to compare if you change medications.
Track Your Protocol in Shotlee
Free dose logging, weight trends, lab snapshots, and side effect tracking.
